Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Sees Significant Drop in Short Interest

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a significant decrease in short interest in April. As of April 15th, there was short interest totaling 3,507 shares, a decrease of 59.9% from the March 31st total of 8,751 shares. Based on an average daily volume of 29,181 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the shares of the stock are short sold.

Hedge Funds Weigh In On Matinas Biopharma

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC bought a new position in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned approximately 0.72% of Matinas Biopharma at the end of the most recent quarter. 11.77% of the stock is currently owned by hedge funds and other institutional investors.

Matinas Biopharma Stock Performance

Shares of MTNB stock remained flat at $0.61 during trading hours on Tuesday. 21,798 shares of the stock were exchanged, compared to its average volume of 32,308. Matinas Biopharma has a 12 month low of $0.48 and a 12 month high of $3.09. The business has a fifty day moving average price of $0.58 and a two-hundred day moving average price of $0.80. The firm has a market cap of $3.91 million, a P/E ratio of -0.30 and a beta of 1.39.

Matinas Biopharma (NYSEAMERICAN:MTNB) last announced its earnings results on Tuesday, March 31st. The company reported ($0.26) earnings per share (EPS) for the quarter.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.